These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 33997447)

  • 21. Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment.
    Yokote K; Yamashita S; Arai H; Araki E; Suganami H; Ishibashi S; Of The K-Study Group OB
    Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30736366
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Pemafibrate Therapy on Reducing Small Dense Low-Density-Lipoprotein-Cholesterol Levels in Patients with Hypertriglyceridemia.
    Hida Y; Imamura T; Kinugawa K
    J Clin Med; 2023 Nov; 12(21):. PubMed ID: 37959379
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination.
    Yamashita S; Arai H; Yokote K; Araki E; Matsushita M; Nojima T; Suganami H; Ishibashi S
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31698825
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia.
    Yamashita S; Arai H; Yokote K; Araki E; Suganami H; Ishibashi S;
    J Clin Lipidol; 2018; 12(5):1267-1279.e4. PubMed ID: 30077640
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic effects of fluvastatin extended release 80 mg and atorvastatin 20 mg in patients with type 2 diabetes mellitus and low serum high-density lipoprotein cholesterol levels: a 4-month, prospective, open-label, randomized, blinded-end point (probe) trial.
    Bevilacqua M; Guazzini B; Righini V; Barrella M; Toscano R; Chebat E
    Curr Ther Res Clin Exp; 2004 Jul; 65(4):330-44. PubMed ID: 24672088
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanism of action of gemfibrozil on lipoprotein metabolism.
    Saku K; Gartside PS; Hynd BA; Kashyap ML
    J Clin Invest; 1985 May; 75(5):1702-12. PubMed ID: 3923042
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elevated Levels of Apolipoprotein CIII Increase the Risk of Postprandial Hypertriglyceridemia.
    Guan Y; Hou X; Tian P; Ren L; Tang Y; Song A; Zhao J; Gao L; Song G
    Front Endocrinol (Lausanne); 2021; 12():646185. PubMed ID: 33967959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinct Differences in Lipoprotein Particle Number Evaluation between GP-HPLC and NMR: Analysis in Dyslipidemic Patients Administered a Selective PPARα Modulator, Pemafibrate.
    Yamashita S; Okazaki M; Okada T; Masuda D; Yokote K; Arai H; Araki E; Ishibashi S
    J Atheroscler Thromb; 2021 Sep; 28(9):974-996. PubMed ID: 33536398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of fenofibrate on albuminuria in patients with hypertriglyceridemia and/or hyperuricemia: a multicenter, randomized, double-blind, placebo-controlled, crossover study.
    Kazumi T; Hirano T; Yoshino G; For The Fenofibrate Study Group
    Curr Ther Res Clin Exp; 2003 Jul; 64(7):434-46. PubMed ID: 24944394
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of triglyceride concentration on the relationship between lipoprotein cholesterol and apolipoprotein B and A-I levels.
    Leroux G; Lemieux I; Lamarche B; Cantin B; Dagenais GR; Lupien PJ; Després JP
    Metabolism; 2000 Jan; 49(1):53-61. PubMed ID: 10647064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial.
    Ishibashi S; Yamashita S; Arai H; Araki E; Yokote K; Suganami H; Fruchart JC; Kodama T;
    Atherosclerosis; 2016 Jun; 249():36-43. PubMed ID: 27062408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice.
    Sairyo M; Kobayashi T; Masuda D; Kanno K; Zhu Y; Okada T; Koseki M; Ohama T; Nishida M; Sakata Y; Yamashita S
    J Atheroscler Thromb; 2018 Feb; 25(2):142-152. PubMed ID: 28781340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Significant Increase of Estimated Glomerular Filtration Rate After Switching From Fenofibrate to Pemafibrate in Type 2 Diabetic Patients.
    Yanai H; Katsuyama H; Hakoshima M
    Cardiol Res; 2021 Dec; 12(6):358-362. PubMed ID: 34970366
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased production rates of LDL are common in individuals with low plasma levels of HDL cholesterol, independent of plasma triglyceride concentrations.
    Ginsberg HN; Ngai C; Wang XJ; Ramakrishnan R
    Arterioscler Thromb; 1993 Jun; 13(6):842-51. PubMed ID: 8499404
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Efficacy and Safety of Low-Dose Pemafibrate in Patients With Severe Renal Impairment: A Retrospective Study.
    Shima H; Tashiro M; Inoue T; Okada K; Okamoto T; Wariishi S; Doi T; Minakuchi J
    Cureus; 2024 Apr; 16(4):e57777. PubMed ID: 38715994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lipids, lipoproteins and apolipoproteins AI, AII, B, CII, CIII and E in newborns.
    Averna MR; Barbagallo CM; Di Paola G; Labisi M; Pinna G; Marino G; Dimita U; Notarbartolo A
    Biol Neonate; 1991; 60(3-4):187-92. PubMed ID: 1797121
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia.
    Fruchart JC
    Cardiovasc Diabetol; 2017 Oct; 16(1):124. PubMed ID: 28978316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of pemafibrate, a novel selective peroxisome proliferator-activated receptor-alpha modulator (SPPARMα), on urinary protein excretion in IgA nephropathy with hypertriglyceridemia.
    Tanaka A; Nakamura T; Sato E; Chihara A; Node K
    CEN Case Rep; 2020 May; 9(2):141-146. PubMed ID: 31950425
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apolipoprotein CIII deficiency prevents the development of hypertriglyceridemia in streptozotocin-induced diabetic mice.
    Takahashi T; Hirano T; Okada K; Adachi M
    Metabolism; 2003 Oct; 52(10):1354-9. PubMed ID: 14564689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipoprotein abnormalities in chronic renal failure and dialysis patients.
    Monzani G; Bergesio F; Ciuti R; Rosati A; Frizzi V; Serruto A; Vitali D; Benucci A; Tosi PL; Bandini S; Salvadori M
    Blood Purif; 1996; 14(3):262-72. PubMed ID: 8738541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.